Recursion Pharmaceuticals, Inc. RXRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 5%— | —— | 4.5%— | —— | |
| Operating margin | -867.9%-53.8pp | -814.1%-28.8pp | -785.3%-169pp | -616.7%+1,179pp | |
| Net margin | -863.4%-75.3pp | -788%-52.0pp | -736%-135pp | -601%+1,231pp | |
| EBITDA margin | -755.8%-3.7pp | -752.1%-21.5pp | -730.6%-143pp | -587.2%+1,126pp | |
| Free cash flow margin | -506.5%+127pp | -633.7%+38.7pp | -672.4%-370pp | -302.6%+1,647pp | |
| Returns | |||||
| Return on equity | -59.5%+2.4pp | -61.9%+7.2pp | -69.1%-22.6pp | -46.6%— | |
| Return on assets | -44.1%0.0pp | -44.1%+4.3pp | -48.4%-11.9pp | -36.5%+4.5pp | |
| Return on invested capital | -124.6%+16.3pp | -141%— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 5.5×+1.7× | 3.8×-0.9× | 4.7×-1.0× | 5.7×-5.8× | |
| Quick ratio | 5.5×+1.7× | 3.8×-0.9× | 4.7×-1.0× | 5.7×-5.8× | |
| Cash ratio | 5.1×+1.9× | 3.2×-1.1× | 4.3×-1.3× | 5.6×-0.8× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $2.53-33.0% | $3.77+69.3% | $2.23-19.4% | $2.77-36.1% | |
| Valuation | |||||
| Market capitalization | $2.13B-19.4% | $2.64B+14.9% | $2.3B+60.6% | $1.43B-51.0% | |
| Enterprise value | $1.47B-32.3% | $2.17B+11.6% | $1.95B+111% | $923.31M-65.5% | |
| Price / sales | 28.5×-16.4× | 44.9×-6.7× | 51.6×+15.6× | 35.9×-251× | |
| Price / book | 1.9×-0.7× | 2.6×-2.4× | 5×+2.0× | 2.9×-2.4× | |
| EV / sales | 19.7×-17.2× | 36.9×-6.8× | 43.7×+20.5× | 23.2×-240× | |
| Free cash flow yield | -17.8%-3.7pp | -14.1%-1.1pp | -13%-4.6pp | -8.4%-1.6pp | |
| Earnings yield | -30.3%-12.7pp | -17.6%-3.3pp | -14.3%+2.5pp | -16.7%-10.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Recursion Pharmaceuticals, Inc. (RXRX) runs a 7.2% gross margin and a -881.3% operating margin, with a -842.9% net margin.
- Where do Recursion Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Recursion Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.